lung cancer

[Merck] Merck announced that the Phase III KEYNOTE-091 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, met one of its dual primary endpoints of disease-free survival for the adjuvant treatment of patients with stage IB-IIIA non-small cell lung cancer following surgical resection regardless of PD-L1 expression.

[Cell Death & Disease] Researchers identified neurokinin-1 as a significantly upregulated GPCR in the transcriptome and tissue array of human lung cancer samples, associated with advanced clinical stages and poor prognosis.

[Journal of Clinical Oncology] The authors report the current status of first-line immunotherapy in metastatic non–small cell lung cance together with current challenges in selecting the best immunotherapeutic approach for the individual patient.

[Journal of Cellular Biochemistry] To investigate the function of factor binding inducer of short transcripts-1 (FBI-1) in epithelial-to-mesenchymal transition (EMT) in lung cancer, EMT was measured in FBI-1-deficient or FBI-1-overexpressing cells.

[Genprex, Inc.] Genprex, Inc. announced that the FDA has granted Fast Track Designation for the Company’s lead drug candidate, REQORSA™ Immunogene Therapy, in combination with Merck & Co’s Keytruda® in patients with histologically-confirmed unresectable stage III or IV non-small cell lung cancer whose disease progressed after treatment with Keytruda.

[Cancer Communications] Murine CMT167 lung cancer cells were engineered to express the firefly luciferase gene and implanted orthotopically in the lung of syngeneic mice. Bioluminescence imaging, flow cytometry, and immunohistochemistry were employed to determine response to immunotherapy and function of tumor-infiltrating immune cells.